Background and study aim: Brain Natriuretic Peptide (BNP) and N-Terminal pro-Brain Natriuretic Peptide (NT-pro BNP) are frequently used in the diagnosis of congestive heart failure (CHF), especially for distinguishing between patients with dyspnea of cardiac and pulmonary origin. The present work aimed at evaluating NTerminal pro-Brain Natriuretic Peptide (NT-proBNP) as a biomarker for diagnosis of congestive heart failure (CHF) in pediatrics and as well as its severity and hence, helping early diagnosis of CHF in absence of rapid echocardiographic examination.
Subjects and Methods:
The patients group (group I) consisted of 45 children (24 males and 21 females) aging between 45 days and 12 years. All having the inclusion criterion of CHF. They were subclassified into: group I-1 including 15 patients having dilated cardiomyopathy (DCM), group I-2 including 15 patients having congenital heart disease (CHD) and group I-3 including 15 patients that have developed CHF due to non-cardiac causes. The control group was formed of 15 healthy children (group II) matched in age and gender with the patients groups. All children were subjected to full history taking, physical examination, classification of clinical severity of CHF cases according to Modified Ross Score, imaging and laboratory investigations including serum level of NT-proBNP.
Results:
The study revealed that serum NT-proBNP showed a highly statistically significant increase in CHF cases three groups (I-1, I-2 and I-3) in comparison to the control group (group II) (P<0.001). NT-proBNP level showed highly statistically significant positive correlation with CHF class of clinical severity (P<0.001). Regarding echocardiographic parameters NT-proBNP showed a highly significant positive correlation with left ventricular end diastolic dimensions (LVEDD) and left ventricular end systolic dimensions (LVESD), and a highly significant negative correlation with left ventricular (LV) ejection fraction (EF), fractional shortening (FS) and mitral valve E/A ratio. At cutoff level of 1500 pg/ml, the sensitivity of NT-proBNP as a diagnostic biomarker in children with CHF was 98% and the specificity was 100%.
INTRODUCTION
CHF is a clinical syndrome where the heart is unable to provide the output required to meet the metabolic demands of the body; however, the causes and mechanisms of CHF are B-type natriuretic peptide (BNP) is a member of a four natriuretic peptide family that shares a common 17-peptide ring structure. The N-terminal fragment (NT-pro-BNP) is biologically inert, but both are secreted in the plasma in equimolar quantities and both have been evaluated for use in the management of CHF [9] . BNP stimulates natriuresis and vasodilation with consequent afterload reduction, inhibits renin-angiotensinaldosterone release and sympathetic nervous activity, and reduces fibrosis. BNP and NT-pro-BNP are frequently used in the diagnosis of CHF and distinguishing between patients with dyspnea of cardiac or pulmonary origin. 'Normal' values of these peptides vary depending on the type of test used. The performance characteristics of these tests vary depending on the patients on whom they are used and the manufacturer. For this reason, the determination of reference values for this peptide represents such a challenge [9] .
SUBJECTS AND METHODS
This case control study was carried out at Pediatric Cardiology Unit, Pediatric Intensive Care Unit and Medical Biochemistry Department in Zagazig University Hospitals during the period from March 2012 to September 2014.
Subjects :
The study covered 60 subjects that will be divided into the following groups:
Group I : (CHF patients):
Forty five patients in pediatric age groups ranging between 1.5 months and 12 years, 21 (46.7%) males and 24 (53.3%) females. All the patients in group I have the inclusion criterion of having clinical CHF signs and symptoms, and they will be subdivided into 3 groups: Group I-1: Fifteen patients having DCM.
Group I-2:
Fifteen patients having CHD : 7 cases of common atrio-ventricular canal (CAVC) (47%), 3 cases of combined atrial septal defect (ASD) and ventricular septal defect (VSD) (20%), 2 cases of combined ASD, VSD and pulmonary stenosis (PS) (13%), one case VSD (6.7 %), one case of double inlet left ventricle (DILV) ( 6.7%) and one case of tricuspid atresia (6.7%).
Group I-3:
Fifteen patients that developed CHF secondary to non cardiac causes involving: 6 cases of severe pneumonia (40%), 4 cases of acute severe asthma (27%), one case of severe bronchiolitis (6.7%), one case of severe bronchopneumonia (6.7%), one case of Acute Respiratory distress Syndrome(ARDS) (6.7%), one case of right lung collapse (6.7%) and one case of anemic heart failure on top of acute severe hemolysis(6.7%).
Exclusion criteria including:
1-Recent cardiopulmonary surgery. 2-Current hemodialysis.
Group II (control group):
Fifteen healthy individual as a control group, the subjects of this group are matched in age and gender to the patients groups.
All children in this study were subjected to complete history taking, general examination including vital signs and anthropometric measures, cardiac examination, chest examination, abdominal examination and clinical assessment of CHF with grading of severity according to Modified Ross Score.
X-ray chest and heart and standard 12 lead Electrocardiography (ECG) were performed. Echocardiographic study was performed in all patients using Ultrasound Machine, Vivid7 (GE medical system, Horten, Norway). Echocardiographic examination included LVEDD, LVESD, and LV systolic function in the form of left ventricular EF and FS using two-dimensional echocardiography and M-mode echocardiography. Also mitral valve E/A ratio was performed by continuous wave (CW) Doppler. By echocardiography, EF % <50% was systolic heart failure and mitral valve E/A ratio <1 was diastolic heart failure (10) .
Blood for NT-proBNP assay was taken from peripheral venous puncture (3 ml) and collected in serum separator tubes (SST) within 3 hours of Some echocardiographic diameters left ventricular EF, FS and mitral valve E/A ratio) showed statistically highly significant decrease in the three groups of cases (groups I-1, I-2 and I-3) compared to the control group (group II) with p value < 0.001, while LVEDD and LVESD showed statistically highly significant increase in the three groups of cases (groups I-1, I-2 and I-3) compared to the control group (group II) with p value <0.001 ( Table 2 , Fig. 1 ), but there is statistically non significant difference between groups of cases (groups I-1, I-2 and I-3) regarding the echocardiographic parameters (EF, FS, LVEDD, LVESD and mitral valve E/A). The serum level of NT-proBNP showed statistically highly significant statistical increase in groups of cases (I-1, I-2 and I-3) compared to the control group (group II) with p value < 0.001. (Table 3 , Fig. 2 ), but there is statistically non significant difference between the three groups of cases regarding the serum level of NTproBNP with p value > 0.05 (Table 4) . Fig. 3 ). Also, The serum level of NT-proBNP showed statistically highly significant increase in cases of HFpEF compared to control group with p value <0.001 (Table 7 , Fig. 3 ). 
Figure (3): Comparison between cases of HFpEF and cases of HFrEF regarding the erusm level of NT-p roBNP
There is highly significant statistical positive correlation between serum NT-proBNP and Modified Ross Score in the 45 cases of CHF with p value <0.001. NT-proBNP showed statistically highly significant positive correlations with LVEDD and LVESD with p value < 0.001 for each, and highly significant negative correlations with left ventricular EF and FS with p value <0.001 for each item, and statistically significant negative correlation with mitral valve E/A ratio with p value = 0.001. Serum NT-proBNP showed non statistically significant correlations with age, body weight, length, heart rate, respiratory rate and CBC parameters in the 45 cases of CHF (Table 8 , Fig.  4-8) . The best cutoff value of NT-proBNP in diagnosis of CHF was 1500 pg/ml with 98% sensitivity and 100% specificity and the p value <0.001 (Table 9) . . In this study, we hypothesize that changes in NT-proBNP serum levels are associated with changes in echocardiographic indices of LV systolic and diastolic function in children in CHF in cases of DCM, CHD and CHF of non cardiac origin, so we studied whether the rapid bedside determination of NTproBNP level could be used for diagnosis of CHF and to predict the severity. Our results showed there is no correlation between serum NT-proBNP and patients' age, body weight, length, heart rate, respiratory rate and CBC parameters (HB, RBCs, WBCs and platelets) in group I (45 CHF patients) . But we found statistically highly significant positive correlation between serum NT-proBNP and the class of clinical severity according to Modified Ross Score with p value <0.001. Regarding echocardiographic parameters NT-proBNP showed highly significant positive correlation with LVEDD and LVESD, and highly significant negative correlation with ejection fraction and fractional shortening with p value <0.001. Also, NT-proBNP showed significant negative correlation with mitral valve E/A ratio with p value = 0.001. Elwan et al. supported our study as they found significant positive correlations between NT-proBNP concentration with LVEDD, LVESD, systolic pulmonary artery pressure (SPAP), and shunt size, and there was significant negative correlation with EF and FS, in cases of CHD (ASD, VSD with and without CHF), but in our study we did not examine SPAP and their study did not include mitral valve E/A ratio [16] .
The results of our study showed that, using a cutoff point of NT-proBNP as 1500 pg/ml, the sensitivity of NT-proBNP as a diagnostic biomarker in children with CHF was 98% and the specificity was 100%. This has agreement with Zoair et al. who used a cutoff point of NT-proBNP as 1500 pg/ml as a diagnostic biomarker in children with DCM, the sensitivity was 85% and the specificity was 100% [15]. However, Rusconi et al. who studied CHF in 36 pediatric patients with DCMfound that NT-proBNP level above 1000 pg/ml clearly identified the sickest patients. NT-proBNP levels between 450 and 1000 pg/ml did not distinguish between symptomatic and asymptomatic patients [20] . With a marked difference from our study, Narin et al. used the NT-proBNP cut off value of 174.3 pg/ml to distinguish healthy children from the patients with left ventricular systolic dysfunction caused by cardiomyopathy [18] , this may be due to the difference in properties of the kit used.
NT-ProBNP level is significantly elevated in CHF with different causes ( DCM, CHD and non cardiac causes of CHF) and in cases of HFpEF in pediatric age. So, we recommend the use of NTProBNP as a routine marker for diagnosing suspected patients with symptoms and signs suggesting CHF for rapid evaluation of cardiac functions, especially in absence of reachable echocardiographic examination.
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